Zoledronic acid is a third-generation, nitrogen-containing bisphosphonate administered as a once-yearly intravenous infusion. It is a potent inhibitor of osteoclast-mediated bone resorption, used primarily for the treatment of osteoporosis, Paget's disease of bone, and the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors or multiple myeloma. In the Indian context, it is a cost-effective alternative to more frequent oral bisphosphonates, improving adherence.
Adult: Osteoporosis/Paget's: 5mg as a single intravenous infusion over at least 15 minutes, once per year. Oncology (SRE prevention): 4mg as a single intravenous infusion over at least 15 minutes, every 3-4 weeks.
Note: Must be administered as a single IV infusion in 100ml of 0.9% Sodium Chloride or 5% Dextrose solution, over NO LESS THAN 15 MINUTES. Use a dedicated IV line. Ensure patient is adequately hydrated (consider 500ml oral/IV fluids pre-infusion). Do not mix with calcium-containing solutions (e.g., Ringer's Lactate). Monitor for acute phase reaction post-infusion.
Zoledronic acid inhibits osteoclast-mediated bone resorption. It acts by binding preferentially to sites of high bone turnover, where it is internalized by osteoclasts. Inside the cell, it inhibits the enzyme farnesyl pyrophosphate synthase (FPPS) in the HMG-CoA reductase pathway (mevalonate pathway).
Pregnancy: Pregnancy Category D (US FDA). Contraindicated. Bisphosphonates can cause fetal harm, including skeletal abnormalities. They are incorporated into the maternal skeleton and can be released over years, posing a theoretical risk even after discontinuation.
Driving: Generally safe. However, patients may experience fatigue, dizziness, or blurred vision (rare) shortly after the infusion. Caution is advised for 24-48 hours post-infusion.
| Aminoglycosides (e.g., Gentamicin) | Additive hypocalcemic effect; increased risk of severe hypocalcemia. | Major |
| Loop Diuretics (e.g., Furosemide) | May increase risk of hypocalcemia. Monitor calcium levels. | Moderate |
| Nephrotoxic drugs (e.g., NSAIDs, Vancomycin, IV Contrast) | Increased risk of renal impairment. Avoid concurrent use or ensure adequate hydration and monitoring. | Major |
| Thalidomide | Increased risk of renal dysfunction in multiple myeloma patients. | Moderate |
| Calcium supplements / Vitamin D | Essential for patient care but should NOT be administered simultaneously via the same IV line. Oral supplements are recommended. | Minor (Administrative) |